|
| 37055346 | Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop. | | 2023 |
| 35658469 | Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. | Journal of Clinical Oncology | 2023 |
| 36357295 | Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study. | Clinical Lymphoma, Myeloma and Leukemia | 2023 |
| 36018226 | Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma. | Blood advances | 2023 |
| 36327160 | Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. | Blood | 2023 |
| 36200130 | Trial designs and endpoints for immune therapies in multiple myeloma. | American Journal of Hematology | 2023 |
| 36411210 | Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2023 |
| 37592106 | Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. | | 2023 |
| 37743180 | Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study. | | 2023 |
| 37733312 | Case 29-2023: A 34-Year-Old Woman with Abdominal Distention and Acute Kidney Injury. | | 2023 |
| 37716872 | Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. | | 2023 |
| 37984714 | Real-world Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect® MM Registry. | | 2023 |
| 37772981 | Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups. | | 2023 |
| 37769148 | IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. | | 2023 |
| 37158935 | Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. | | 2023 |
| 37403937 | Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma. | | 2023 |
| 37270762 | Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma. | | 2023 |
| 37014590 | Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma. | | 2023 |
| 36567211 | Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry. | | 2023 |
| 37190297 | What Affects Treatment Underuse in Multiple Myeloma in the United States: A Qualitative Study. | | 2023 |
| 36546453 | Adjusted comparison of outcomes between patients from CARTITUDE-1 multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world cl | | 2023 |
| 34588149 | Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 35846215 | Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. | | 2022 |
| 36243663 | Dupilumab in Multiple Myeloma: A Case Series. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 35768410 | Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. | Blood Cancer Journal | 2022 |
| 35704796 | A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. | JCO Precision Oncology | 2022 |
| 35579821 | Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States. | Oncology and Therapy | 2022 |
| 36215989 | Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. | Lancet Haematology,The | 2022 |
| 36209764 | Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. | Lancet Haematology,The | 2022 |
| 35361554 | Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 35978321 | Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. | Journal of Hematology and Oncology | 2022 |
| 35660812 | Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. | N Engl J Med | 2022 |
| 34736880 | The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 34670732 | Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 35210399 | Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. | Blood Cancer Journal | 2022 |
| 34840088 | Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 35113384 | Targeting Nuclear Export Proteins in Multiple Myeloma Therapy. | BioDrugs | 2022 |
| 34822128 | Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. | Clinical Drug Investigation | 2022 |
| 34529955 | Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. | Lancet Haematol | 2021 |
| 35846096 | Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. | | 2021 |
| 34243048 | Multiple myeloma, race, insurance and treatment. | Cancer Epidemiol | 2021 |
| 33755235 | Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. | American Journal of Hematology | 2021 |
| 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet, The | 2021 |
| 34062004 | Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. | American Journal of Hematology | 2021 |
| 33849608 | Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. | Journal of Hematology and Oncology | 2021 |
| 33735504 | Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. | Cancer | 2021 |
| 34161627 | Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. | American Journal of Hematology | 2021 |
| 33613930 | Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. | Therapeutic Advances in Hematology | 2021 |
| 34145225 | KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. | Blood Cancer Journal | 2021 |
| 33608053 | Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. | Journal of Medical Case Reports | 2021 |